Affordable Access

deepdyve-link
Publisher Website

The network of immunosuppressive pathways in glioblastoma.

Authors
  • Mangani, Davide1
  • Weller, Michael2
  • Roth, Patrick3
  • 1 Laboratory of Molecular Neuro-Oncology, Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland. , (Switzerland)
  • 2 Laboratory of Molecular Neuro-Oncology, Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland; Center for Neuroscience, University of Zurich, Zurich, Switzerland. , (Switzerland)
  • 3 Laboratory of Molecular Neuro-Oncology, Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland; Center for Neuroscience, University of Zurich, Zurich, Switzerland. Electronic address: [email protected] , (Switzerland)
Type
Published Article
Journal
Biochemical pharmacology
Publisher
New York, NY : Elsevier Science Inc
Publication Date
Apr 15, 2017
Volume
130
Pages
1–9
Identifiers
DOI: 10.1016/j.bcp.2016.12.011
PMID: 28017775
Source
Medline
Keywords
License
Unknown

Abstract

Glioblastoma remains a fatal tumor despite increased knowledge regarding the complex signalling pathways that drive this devastating disease. Recently, immunotherapeutic approaches have shown remarkable and durable responses in various cancers including metastatic melanoma and advanced non-small cell lung cancer. So far, it remains unclear whether these immunotherapeutics may also work against glioblastoma and other tumors residing in the central nervous system. It is well known that patients with glioblastoma suffer from profound local immunosuppression that represents the major hurdle to overcome in the context of immunotherapy. Several studies have demonstrated that this immunosuppressive phenotype is orchestrated by glioma-derived membrane-bound and soluble factors as well as the particular microenvironment within the brain. Here, we discuss the molecular and cellular pathways involved in glioblastoma-mediated inhibition of the immune system and highlight possible treatment approaches aiming at reinvigorating anti-tumor immune responses.

Report this publication

Statistics

Seen <100 times